Zenas BioPharma nomme Simon Lowry, M.D. au poste de directeur médical

WALTHAM, Mass. et SHANGHAI, Chine, 07 sept. 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de thérapies immunitaires pour les patients dans le besoin à travers le monde, a annoncé aujourd’hui la nomination de Simon Lowry, M.D., au poste de directeur médical de la société. Le Dr Lowry apporte plus de 20 ans d’expertise clinique dans la conception et l’exécution de programmes cliniques de stade précoce à avancé à Zenas, où il dirigera les fonctions cliniques, médicales et de pharmacovigilance de la société au niveau international.

« Nous sommes ravis d’accueillir le Dr Lowry au sein de Zenas à ce moment crucial pour la société, alors que nous commençons deux essais d’enregistrement de phase trois pour notre principal produit candidat, l’obexelimab, au quatrième trimestre de cette année, et que nous entamons les premiers essais cliniques sur l’homme pour plusieurs programmes en cours », a déclaré Hua Mu, M.D., Ph. D, président-directeur général de Zenas. « Le leadership éprouvé du Dr Lowry, sa vaste expérience du développement clinique et sa grande expérience en matière d’essais cliniques à l’échelle mondiale renforceront davantage notre capacité à mener à bien notre mission, qui consiste à transformer la vie des patients dont les besoins médicaux ne sont pas satisfaits, en leur proposant les meilleurs traitements immunitaires de leur catégorie. »

Le Dr Simon Lowry a ajouté : « De nombreux patients atteints de maladies rares et auto-immunes ont besoin d’options thérapeutiques nouvelles et efficaces. L’équipe de Zenas, très expérimentée et talentueuse, a considérablement développé son portefeuille en très peu de temps, et je suis impatient de diriger l’avancement continu des programmes cliniques de Zenas jusqu’à la commercialisation, tout en renforçant le portefeuille de programmes innovants de la société. »

Le Dr Lowry est un médecin possédant 20 ans d’expérience dans des sociétés pharmaceutiques et biotechnologiques importantes et émergentes, où il a dirigé des programmes de développement fructueux, des équipes d’affaires cliniques et médicales, et interagi avec des organismes de réglementation dans plusieurs domaines de la médecine, y compris la rhumatologie, l’immunologie et l’ophtalmologie. Avant de rejoindre Zenas, le Dr Lowry était directeur médical chez Kinevant Science, une société biopharmaceutique au stade clinique, spécialisée dans le traitement des maladies inflammatoires et auto-immunes rares. Le Dr Lowry était auparavant responsable de la R&D en immunologie chez Roivant Sciences, où il dirigeait tous les actifs de l’immunologie en phase de développement clinique, et était un membre clé de l’équipe de direction. Il a également occupé le poste de directeur médical chez Sun Pharma North America, où il était responsable de quatre domaines thérapeutiques de marque (immunologie et dermatologie, ophtalmologie, neurologie et oncologie), et a dirigé tous les aspects du développement et des fonctions médicales (y compris le développement clinique, les informations médicales, la médecine de terrain, La recherche sur l’économie et les résultats de la santé (HEOR), les publications/communications médicales et les opérations). Au début de sa carrière, il a travaillé chez Novartis, où il a occupé le poste de vice-président, directeur de franchise des affaires médicales mondiales, immunologie et dermatologie, et chez Pfizer, où il a occupé des postes à responsabilité croissante, notamment celui de vice-président du groupe des affaires médicales en oncologie.

Avant sa carrière dans le secteur pharmaceutique/biotechnologique, le Dr Lowry a pratiqué la médecine interne dans diverses institutions au Royaume-Uni et en Australie. Il a obtenu son BA au Trinity Hall, de l’université de Cambridge, au Royaume-Uni et son diplôme médical MB BChir à la Cambridge University School of Clinical Medicine.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le monde entier. Avec un développement clinique et des activités aux États-Unis et en Chine, Zenas fait rapidement progresser un important programme de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs,” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma Nomeia Simon Lowry, M.D. para Diretor Médico

WALTHAM, Mass. e SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas, anunciou hoje a nomeação de Simon Lowry, MD para seu Conselho Diretor. O Dr. Lowry tem mais de 20 anos de ampla experiência clínica na concepção e execução de programas clínicos de estágio inicial a final na Zenas, onde ele passará a liderar as funções globais de clínica, assuntos médicos e farmacovigilância da empresa.

“Estamos muito contentes em receber o Dr. Lowry na Zenas neste momento crucial para a empresa, quando damos início a dois testes de registro de fase três do nosso principal candidato a produto, obexelimabe, no quarto trimestre deste ano, e aos primeiros testes clínicos em humanos de vários programas de pipeline”, disse Hua Mu, M.D., Ph.D., Diretor Executivo da Zenas. “A liderança comprovada do Dr. Lowry, seu amplo histórico de desenvolvimento clínico e extensa experiência com ensaios clínicos globais irão fortalecer ainda mais nossa capacidade de executar nossa missão de transformar a vida dos pacientes com necessidades médicas não atendidas, com a oferta das melhores terapias imunológicas aos pacientes.”

O Dr. Simon Lowry acrescentou: “Há muitos pacientes com doenças autoimunes e raras que precisam de novas opções de tratamento eficazes. A equipe profundamente experiente e talentosa da Zenas fez um progresso impressionante ao avançar no pipeline da empresa em um período muito curto de tempo, e estou pronto para liderar o avanço contínuo dos programas clínicos da Zenas com a sua comercialização e maior expansão do pipeline de programas inovadores da empresa.”

O Dr. Lowry tem 20 anos de experiência com grandes empresas farmacêuticas e de biotecnologia emergentes, tendo dirigido programas de desenvolvimento bem-sucedidos, liderado equipes de assuntos clínicos e médicos, e interagido com agências reguladoras em várias áreas da medicina, incluindo reumatologia, imunologia e oftalmologia. Antes de ingressar na Zenas, o Dr. Lowry foi Diretor Médico da Kinevant Science, uma empresa biofarmacêutica de estágio clínico focada no tratamento de doenças inflamatórias e autoimunes raras. Anteriormente, o Dr. Lowry foi Chefe de Pesquisa e Desenvolvimento em Imunologia da Roivant Sciences, liderando todos os ativos de imunologia em estágio de desenvolvimento para o desenvolvimento clínico, e serviu como um membro-chave da equipe de liderança. Ele também atuou como Diretor Médico na Sun Pharma North America, onde foi responsável por quatro áreas terapêuticas de marca (Imunologia e Dermatologia, Oftalmologia, Neurologia e Oncologia) e liderou todos os aspectos do desenvolvimento e funções médicas (incluindo desenvolvimento clínico, informações médicas, medicina de campo, HEOR, publicações/comunicações médicas e operações). No início da sua carreira, ele trabalhou na Novartis, onde atuou como Vice-Presidente, Chefe de Franquia de Assuntos Médicos Globais, Imunologia e Dermatologia, e na Pfizer, onde atuou em funções de responsabilidade crescente, incluindo como Vice-Presidente, Líder do Grupo de Assuntos Médicos de Oncologia.

Antes da sua carreira farmacêutica/biotecnológica, o Dr. Lowry exerceu medicina interna em várias instituições no Reino Unido e na Austrália. Ele é formado em Medicina pela Trinity Hall, Cambridge University e pela Cambridge University School of Clinical Medicine no Reino Unido.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes em todo o mundo. Com desenvolvimento clínico e operações nos EUA e na China, a Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

IPLOOK Chosen by Oceanlink to Enable the Delivery of 4G Mobile Network on Pacific Islands

IPLOOK’ s MNO solution allows Oceanlink to quickly and economically deliver 4G network services to its mobile users; Achieving IPLOOK’ s first commercial 2G&3G&4G LTE deployment (CSFB Feature) in Kiribati

HONG KONG, Sept. 7, 2022 /PRNewswire/ —  IPLOOK Technologies, the leader in end-to-end LTE/5G mobile core network vendor, announced it has been chosen by Oceanlink, a Mobile Network Operator (MNO) in Kiribati, to provide its 4G mobile core network for commercial deployment on Pacific Islands. This deployment enables Oceanlink to address the high-performance and stable network demands, expanding its service offerings to customers.

On the islands of Kiribati, the legacy 2G/3G network connection is not developed as quickly as the growing market demand for high-speed internet and multiple media services. By deploying IPLOOK’s carrier-grade  EPC and IMS platform, Oceanlink achieved a swift rollout of the new-built 4G commercial network while significantly lowering the total cost of ownership (TCO) and reducing overall time to market, delivering its customers a truly seamless connectivity experience with less network disruption.

“To satiate customers’ demands for highly reliable network connectivity, we chose IPLOOK as our partner. Backed up by an excellent team to undertake this network transformation, we are well-positioned to address future growth and expansion,” said Liyong Liang, CTO of ACCLINKS.

“We are excited to work with ACCLINKS to expand mobile services and cost-effectively scale their networks by leveraging our MNO solution,” said Owen Ouyang, Region Director in the MENA region of IPLOOK, “This cooperation is a prime example of our high-quality and easy-to-deploy network solution that accelerates operators’ ability to create revenue opportunities.”

About Oceanlink

ACCLINKS (Branded as “Oceanlink”) has been serving customers on Pacific Islands since 2003. The company establishes trust with customers through professional services, customized products and quick response. ACCLINKS provides high quality products and top level professional services.

More info at http://www.acclinks.com/.

About IPLOOK

Founded in 2012, IPLOOK is an industry-leading end-to-end, cloud-based mobile network solution provider. IPLOOK’ s highly scalable virtualized 3G/4G/5G core network software products can be deployed in the deployment scenarios for Mobile Network Operators (MNO), Mobile Virtual Network Operators (MVNO), Wireless Internet Services Providers (WISP) and Enterprises.

Reach out more at https://www.iplook.com/. Follow IPLOOK on LinkedIn @IPLOOK Technologies

Contact us:

E-mail: info@iplook.com

Tribert Rujugiro Ayabatwa Welcomes the East African Court of Justice Ruling that Rwanda Government’s Seizure of his Trade Union Centre Mall Was Illegal

TORONTO, Sept. 6, 2022 /PRNewswire/ — Entrepreneur and philanthropist Tribert Rujugiro Ayabatwa is pleased to announce that on August 30, 2022, the East African Court of Justice (EACJ) ruled that Rwanda government’s seizure and auctioning his Union Trade Centre (UTC) Mall were illegal. EACJ awarded Ayabatwa US$1 million, 6% interest and court costs. The government seized the US$20 million Mall in 2013, alleging that UTC was ‘abandoned’ because Ayabatwa who is Rwandan-born resided outside Rwanda. UTC was at the time a thriving business, hosting 80 businesses with nearly 500 employees, managed by a strong local team in good standing with Rwandan authorities. Then in August 2015, the government declared UTC a tax defaulter of US$1.4 million, an absurd claim, since the Mall was managed by the Rwandan state. Two years later, the government auctioned UTC for a mere US$8 million, less than half its actual value.

Union Trade Centre Mall

Ayabatwa took the government to EACJ, which ruled in 2020 that seizure and auctioning UTC were illegal. The government was ordered to account for rental and sale proceeds of UTC from 2013 and to compensate Ayabatwa for damages amounting to US$500,000 and 6% annual interest from the date of judgment. Ayabatwa appealed the ruling, however, because the Court did not restore his ownership of UTC. That is when the government fabricated a new absurd allegation that Ayabatwa and his associates had embezzled US$458,058 from UTC in 2011. The cited ‘crime’ was in fact a loan acquired during the construction of UTC Mall. Now, the Rwandan government has once again lost the UTC Mall case. Ayabatwa welcomed the 30 August 2022 Court ruling, remarking that “there are times when we are powerless to prevent injustice, but with truth on your side, justice always prevails.”

About Tribert Rujugiro Ayabatwa

Tribert Rujugiro Ayabatwa is a successful entrepreneur and philanthropist from Rwanda. He is founder of Pan-African Tobacco Group, Africa’s largest indigenous manufacturer of tobacco products in nine African countries and in the United Arab Emirates, trading across eastern, western and southern Africa. Ayabatwa is one of Africa’s leading philanthropists, assisting communities to uplift themselves in food security, access to clean water, reforestation, education, and engineering internships.

Pan-African Tobacco Group
info@ptg-hld.com
www.ptg-hld.com

Photo – https://mma.prnewswire.com/media/1892959/Tribert_Rujugiro_Ayabatwa__UTC_founder_Tribert_Rujugiro_Ayabatwa.jpg

David Himbara, Pan-African Tobacco Group, info@ptg-hld.comwww.ptg-hld.com

Judge: Musk Can Use Twitter Whistleblower But Not Delay Case

Elon Musk will be able to include new evidence from a Twitter whistleblower as he fights to get out of his $44 billion deal to buy the social media company, but Musk won’t be able to delay a high-stakes October trial over the dispute, a judge ruled Wednesday.

Chancellor Kathaleen St. Jude McCormick, the head judge of Delaware’s Court of Chancery, denied Musk’s request to delay the trial by four weeks. But she allowed the billionaire Tesla CEO to add evidence related to whistleblower allegations by former Twitter security chief Peiter Zatko, who is scheduled to testify to Congress next week about the company’s poor cybersecurity practices.

Twitter has sued Musk, asking the Delaware court to force him to go through with the deal he made in April to buy the company. Musk has countersued and a trial is set to start the week of October 17.

Musk’s legal team has argued that the allegations made by Zatko to U.S. officials may help bolster Musk’s claims that Twitter misled him and the public about the company’s problem with fake and “spam” accounts. Zatko, a well-known cybersecurity expert known by his hacker handle ” Mudge,” said he was fired in January after raising flags about Twitter’s negligence in protecting the security and privacy of its users.

The judge’s ruling followed an hourslong hearing Tuesday at which attorneys for Musk and Twitter argued with each other about the merits of Zatko’s claims and the pace at which both sides are producing evidence ahead of the trial.

Twitter’s attorneys sought to downplay the relevance of Zatko’s allegations to the merger dispute, arguing that an initial 27-page complaint he sent to Twitter and a later retaliation claim made no mention of the “spam bot” issues that Musk has given as a reason to terminate the deal. Zatko “never said a word about spam or bots” until his July whistleblower complaint, said Twitter attorney William Savitt.

Twitter has argued for weeks that Musk’s stated reasons for backing out were just a cover for buyer’s remorse after agreeing to pay 38% above Twitter’s stock price shortly before the stock market stumbled and shares of the electric-car maker Tesla, where most of Musk’s personal wealth resides, lost more than $100 billion of their value.

McCormick, the judge, said Wednesday the newly published whistleblower complaint gave Musk’s team grounds to amend its countersuit but she declined to weigh in on the details.

“I am reticent to say more concerning the merits of the counterclaims at this posture before they have been fully litigated,” she wrote. “The world will have to wait for the post-trial decision.”

McCormick, however, sided with Twitter’s concerns that delaying the trial would make it harder for the company to get back to business.

“I am convinced that even four weeks’ delay would risk further harm to Twitter too great to justify,” she wrote.

In afternoon trading, Twitter shares added 5.5% to $40.77.

Source: Voice of America

Apple Offers Adventure Watch, Satellite SOS iPhone – and Steady Prices

Apple on Wednesday avoided price hikes of its best-selling iPhones during its biggest product launch of the year, focusing on safety upgrades rather than flashy new technical specs, with the exception of a new adventure-focused watch.

The iPhone maker leaned into safety technologies, like the ability to detect a car accident and summon a rescue from a remote mountaintop, to add allure to its devices. Apple positioned itself as the brand to allow users to pursue excitement and adventure — with a safety net.

Such intangible features “are the things that make you not just want the products for yourself, but also for loved ones,” said Ben Bajarin, head of consumer technologies at Creative Strategies. “Ultimately, the increased emphasis on safety — safety as a service — is super interesting as a value proposition.”

The iPhone lineup that generates half of Apple’s sales got tweaks to cameras and battery life, though only the iPhone Pro lineup got an upgrade to a completely new processor chip.

Prices of the high-end iPhone 14s are the same as last year’s iPhone 13 models. But Apple dropped its cheapest option, the iPhone Mini, meaning its lowest-priced model now costs $100 more than last year.

The iPhone 14 will start at $799 and the iPhone 14 Plus at $899 and be available for preorder starting Friday. The iPhone Pro will cost $999 and the iPhone Pro Max $1,099 and be available September 16.

“They decided to essentially maintain pricing despite inflationary pressure,” said D.A. Davidson analyst Tom Forte.

Nintendo and T-Mobile have also said they will hold off on price increases.

Satellite SOS feature

Apple said its satellite SOS feature will work with emergency responders. It also said that users will be able to use its FindMy app to share their location via satellite when they have no other connectivity.

The service will be free for two years with the iPhone 14. Apple did not say what would happen after that period.

Shares in Globalstar jumped 20% on Wednesday after the satellite services firm announced it would be the satellite operator for Apple’s emergency SOS service.

The Cupertino, California-based company also showed a trio of new Apple Watches, including a new Watch Ultra model aimed at extreme sports and diving and designed to challenge sports watch specialists such as Garmin and Polar.

On the watch front, the $799 Ultra has a bigger battery to last through events like triathlons and better waterproofing and temperature resistance to operate in outdoor environments, as well as better GPS tracking for sports.

All of the watches, which include a Series 8 priced the same as last year and an updated, cheaper SE model, and new iPhones will have the ability to detect when a user has been in a serious car crash and call emergency services.

Ovulation detection

The new Series 8 watch has a temperature sensor that will retroactively detect ovulation. The company emphasized the privacy approach of its cycle tracking. Privacy and reproductive health data have become a focus for tech companies in the wake of a U.S. Supreme Court decision that ended a constitutional right to abortion in the United States.

But while accessories like the Apple Watch have driven incremental sales from Apple’s existing user base, the iPhone remains the bedrock of its business with 52.4% of sales in its most recent fiscal year, and investors continue to wonder what, if anything, will be the company’s next major product category.

Analysts expect that category to be a mixed reality headset that could come to market as soon as next year, but Apple gave no hints at those potential products on Wednesday.

Source: Voice of America

Elections2022: Bishop encourages president-elect to preserve peace

Ondjiva – The bishop of the Eastern Diocese of the Evangelical Lutheran Church of Angola (IELA) this Wednesday encouraged the President-elect João Lourenço to work for the preservation of peace and the sustainable growth of the country.

Speaking to ANGOP, regarding the expectations around the formation of the new government, Bishop Tomás Ndawanapo also defended greater commitment to the social sector, with a focus on education, health, higher education and roads.

He considered it necessary more incentives for family farming, the fight against poverty and illiteracy to be fundamental, as well as the creation of more jobs for young people and the increase in the programme to strengthen the system for the protection of vulnerable people.

The prelate also stated that it was necessary to correct what he considered “distortions of moral, social and economic reality”.

The MPLA won the general elections with 51.17% of the votes, followed by UNITA with 43.95%, according to data from the National Electoral Commission (CNE).

With these results, the MPLA won 124 deputies in the National Assembly and UNITA 90, while the FNLA, PRS and PHA each elected two deputies

Source: Angola Press News Agency

Elections2022: Dominican President congratulates João Lourenço on re-election

Luanda – The President of the Dominican Republic, Luis Abinader, on Wednesday congratulated his Angolan counterpart, Joao Lourenço, on his re-election in the general elections held on August 24.

In the message that has reached ANGOP, the Dominican statesman said he wishes that João Lourenço continue to make important contributions for the strengthening of freedom, peacekeeping and solidarity of the Angolan people.

“We trust in the continuity of the excellent diplomatic, commercial and cultural relations that exist between our nations and a renewed impulse of bilateral exchanges between our countries”, reads the message.

According to the definitive results published by the National Electoral Commission (CNE), the MPLA won the elections with 51.17% (3.209,429 votes), resulting in the re-election of its presidential candidate, João Lourenço, for the post of President of the Republic, and also gaining 124 parliamentary seats.

UNITA comes second with 43.95% (2.756.786 votes, winning 90 MPs), PRS 1,14% (71,351 votes, 2 MPs), FNLA 1,06% (66,337 votes, 2 MPs) and PHA with 1,02% (63,749 votes, 2 MPs).

CASA-CE with 0.76% (47,446 votes), APN with 0.48% (30,139 votes) and P-NJANGO with 0.42% (26,867 votes) did not get any MPs.

Source: Angola Press News Agency

Elections2022: Constitutional Court rejects CASA-CE appeal

Luanda – The Constitutional Court (TC) dismissed CASA-CE´s electoral coalition appeal contesting the results of the general elections held on 24 August of the current year in Angola, due to the non-observance of legal procedures.

The Constitutiional Court, which also functions as Electoral Court, states that CASA-CE (Broad Convergence for the Salvation of Angola – Electoral Coalition) filed its appeal refuting the national tabulation of the general elections, on 1st September.

The coalition led by Manuel Fernandes claimed that the definitive results published by the National Electoral Commission (CNE) do not match those of its parallel count.

The electoral coalition appeal mentioned non-compliances in the votes obtained in the provinces of Huambo, Cuanza Norte and Benguela, where the CNE count allegedly gave it fewer votes than it should have.

Due to that, CASA-CE requested the court to order a recount of the votes based on the pre-existing minutes to ensure the election of CASA-CE MP´s to the National Assembly.

In its conclusions, the TC explained that it dismissed the appeal because CASA-CE had not filed a complaint with the CNE.

The court clarifies that under the combined provisions of the Constitution, the electoral law and the Law of Constitutional Procedure, a prior complaint to the CNE, as the entity in charge of organizing and conducting the electoral process at national level, is required for electoral litigation to take place.

The court also said it had found that even if CASA-CE had complied with this legal requirement, its claim would be unfounded because it only submitted evidence for Cuanza Norte, where 849 votes had been counted, according to the compliant summary reports.

According to official results from the CNE, CASA-CE obtained 0.76% of the votes (47,446) not enough to elect a deputy (Mp), losing to the Social Renewal Party (PRS) its position as the country´s third largest political force, which it had won in the 2012 elections.

Meanwhile, Adalberto Costa Júnior, the president of UNITA party also appealed to the Constitutional Court for disagreeing with the results announced by the CNE, which gave victory to the MPLA and its presidential candidate, João Lourenço, with 51.17% of the votes.

The Court has promised to present its conclusions this Thursday on the appeal lodged by UNITA, in order to close the phase of complaints about the election results.

CNE data show that the MPLA obtained about 3.209,000 votes corresponding to 124 parliamentary seats against 2.786,000 votes of UNITA for 90 seats which got 43.95%.

In third position, Benedito Daniel´s of PRS won 71,351 votes (1.14%) two deputies, followed by the National Front for the Liberation of Angola (FNLA) led by Nimi a Nsimbi, and the newcomer Humanist Party of Angola (PHA) of Florbela Catarina Malaquias, with two parliamentary seats each.

The National Patriotic Alliance (APN) led by Quintino Moreira and the Nationalist Party for Justice in Angola (P-NJANGO) of Eduardo “Dinho” Chingunji were also left without seats.

The latter two are exposed to extinction by the Constitutional Court for having fallen below the 0.5% threshold imposed by law for the survival of political parties.

These were the fifth general elections, in Angola, and the first with the participation of the Angolan citizens in the diaspora, after those held in 1992, 2008, 2012 and 2017.

Meanwhile, all four previous editions were won by the MPLA.

Source: Angola Press News Agency